デフォルト表紙
市場調査レポート
商品コード
1007637

ジェネリック医薬品の世界市場:タイプ、用途、投与経路、流通チャネル別-2030年までの業界分析と需要予測

Generic Drugs Market Research Report: By Type, Application, Route of Administration, Distribution Channel - Global Industry Analysis and Demand Forecast to 2030

出版日: | 発行: Prescient & Strategic Intelligence Private Limited | ページ情報: 英文 203 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.57円
ジェネリック医薬品の世界市場:タイプ、用途、投与経路、流通チャネル別-2030年までの業界分析と需要予測
出版日: 2021年03月01日
発行: Prescient & Strategic Intelligence Private Limited
ページ情報: 英文 203 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のジェネリック医薬品の市場規模は、2019年に2,784億ドルとなりました。同市場は、2020年から2030年の間に10%のCAGRで成長する見通しで、2030年には7,860億ドルに達すると予測されています。これは、ブランド医薬品は高価であることが多く、新興国では多くの人々が購入困難であることに起因しています。

世界保健機関(WHO)によると、2020年の死亡者数のほぼ75%は慢性疾患が原因となっています。その中でも特に死亡率が高いのは、虚血性心疾患、糖尿病、がん、脳卒中となっており、これらは世界のジェネリック医薬品市場の成長を後押しする要因となっています。

当レポートは、世界のジェネリック医薬品市場について調査しており、市場規模や予測、機会、成長および抑制要因、タイプ・用途・投与経路・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 調査の背景

  • 調査目的
  • 市場の定義
  • 調査範囲
    • タイプ別の市場セグメンテーション
    • 用途別の市場セグメンテーション
    • 投与経路別の市場セグメンテーション
    • 流通チャネル別の市場セグメンテーション
    • 地域別の市場セグメンテーション
    • 分析期間
    • 市場データレポーティングユニット
  • 主な利害関係者

第2章 調査手法

  • 2次調査
  • 1次調査
    • 1次調査回答者の内訳
      • 地域別
      • 業界参入企業別
      • 企業タイプ別
  • 市場規模の推計
  • データの三角測量
  • 為替レート
  • 調査の前提条件

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 市場の定義
    • タイプ別
      • シンプル
      • スーパー
      • バイオシミラー
    • 用途別
      • 神経疾患
      • 心臓病
      • 代謝性疾患
      • 感染症
      • 整形外科疾患
      • 呼吸器疾患
      • 泌尿生殖器/ホルモン性疾患
      • その他
    • 投与経路別
      • 経口
      • 注射
      • 皮膚
      • 粘膜
      • 吸入
      • その他
    • 流通チャネル別
      • 間接
      • 直接
  • 市場力学
    • 動向
      • ジェネリック医薬品への選好のシフト
      • 製品発売の増加
      • 協業と提携数の増加
      • 合併や買収数の増加
    • 成長要因
      • 高齢化人口の増加
      • ブロックバスター薬剤の特許満了
      • 急性および慢性疾患の有病率の高まり
      • バイオテクノロジーおよび製薬企業の研究開発費の増加
      • 市場予測に対する成長要因の影響分析
    • 抑制要因
      • ジェネリック医薬品に影を落とすブランド薬の高いマーケティング
      • ブランド薬に対する医師の選好
      • 市場予測に対する抑制要因の影響分析
    • 市場機会
      • ジェネリック医薬品の支持規制
  • COVID-19の影響
    • 供給側分析
      • ジェネリック製品の主要な製造業者と輸出業者の現在のシナリオ
      • ロックダウンの状況と労働力の可用性
      • 生産シナリオ
      • ジェネリック医薬品の主要供給国の状況
    • 需要側分析
  • ポーターのファイブフォース分析

第5章 世界の市場規模と予測

  • タイプ別
  • 用途別
  • 投与経路別
  • 流通チャネル別
  • 地域別

第6章 北米の市場規模と予測

  • タイプ別
  • 用途別
  • 投与経路別
  • 流通チャネル別
  • 国別

第7章 欧州の市場規模と予測

  • タイプ別
  • 用途別
  • 投与経路別
  • 流通チャネル別
  • 国別

第8章 アジア太平洋の市場規模と予測

  • タイプ別
  • 用途別
  • 投与経路別
  • 流通チャネル別
  • 国別

第9章 ラテンアメリカの市場規模と予測

  • タイプ別
  • 用途別
  • 投与経路別
  • 流通チャネル別
  • 国別

第10章 中東・アフリカの市場規模と予測

  • タイプ別
  • 用途別
  • 投与経路別
  • 流通チャネル別
  • 国別

第11章 競合情勢

  • 主要企業の戦略的開発
    • 製品の発売と承認
    • 提携
  • 主要な企業とその提供物

第12章 企業プロファイル

  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Alkem Laboratories Limited
  • Teva Pharmaceutical Industries Limited
  • Mylan N.V.
  • Lupin Limited
  • Endo International plc
  • Aurobindo Pharma Limited
  • STADA Arzneimittel AG
  • Hikma Pharmaceuticals plc
  • Sawai Pharmaceutical Co. Ltd.
  • Piramal Enterprises Ltd.
  • Mallinckrodt plc
  • Torrent Pharmaceuticals Ltd.
  • Amneal Pharmaceuticals Inc.
  • Taro Pharmaceutical Industries Ltd.
  • Perrigo Company plc
  • Alvogen
  • Nichi-Iko Pharmaceutical Co. Ltd.
  • Glenmark Life Sciences Limited
  • Amphastar Pharmaceuticals Inc.
  • MSN Labs
  • CUSTOPHARM INC.
  • Cadila Healthcare Ltd.
  • Pfizer Inc.
  • Sanofi
  • Bausch Health Companies Inc.

第13章 付録

  • 略語
  • 情報源とリファレンス
  • 関連レポート
図表

LIST OF TABLES

  • TABLE 1 VALUE MARKET SIZE ANALYSIS PERIOD
  • TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS
  • TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS
  • TABLE 4 GLOBAL GENERIC DRUGS MARKET, BY TYPE, $B (2014-2019)
  • TABLE 5 GLOBAL GENERIC DRUGS MARKET, BY TYPE, $B (2020-2030)
  • TABLE 6 GLOBAL GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2019)
  • TABLE 7 GLOBAL GENERIC DRUGS MARKET, BY APPLICATION, $B (2020-2030)
  • TABLE 8 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2019)
  • TABLE 9 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020-2030)
  • TABLE 10 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2019)
  • TABLE 11 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020-2030)
  • TABLE 12 GLOBAL GENERIC DRUGS MARKET, BY REGION, $B (2014-2019)
  • TABLE 13 GLOBAL GENERIC DRUGS MARKET, BY REGION, $B (2020-2030)
  • TABLE 14 NORTH AMERICA GENERIC DRUGS MARKET, BY TYPE, $B (2014-2019)
  • TABLE 15 NORTH AMERICA GENERIC DRUGS MARKET, BY TYPE, $B (2020-2030)
  • TABLE 16 NORTH AMERICA GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2019)
  • TABLE 17 NORTH AMERICA GENERIC DRUGS MARKET, BY APPLICATION, $B (2020-2030)
  • TABLE 18 NORTH AMERICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2019)
  • TABLE 19 NORTH AMERICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020-2030)
  • TABLE 20 NORTH AMERICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2019)
  • TABLE 21 NORTH AMERICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020-2030)
  • TABLE 22 NORTH AMERICA GENERIC DRUGS MARKET, BY COUNTRY, $B (2014-2019)
  • TABLE 23 NORTH AMERICA GENERIC DRUGS MARKET, BY COUNTRY, $B (2020-2030)
  • TABLE 24 EUROPE GENERIC DRUGS MARKET, BY TYPE, $B (2014-2019)
  • TABLE 25 EUROPE GENERIC DRUGS MARKET, BY TYPE, $B (2020-2030)
  • TABLE 26 EUROPE GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2019)
  • TABLE 27 EUROPE GENERIC DRUGS MARKET, BY APPLICATION, $B (2020-2030)
  • TABLE 28 EUROPE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2019)
  • TABLE 29 EUROPE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020-2030)
  • TABLE 30 EUROPE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2019)
  • TABLE 31 EUROPE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020-2030)
  • TABLE 32 EUROPE GENERIC DRUGS MARKET, BY COUNTRY, $B (2014-2019)
  • TABLE 33 EUROPE GENERIC DRUGS MARKET, BY COUNTRY, $B (2020-2030)
  • TABLE 34 APAC GENERIC DRUGS MARKET, BY TYPE, $B (2014-2019)
  • TABLE 35 APAC GENERIC DRUGS MARKET, BY TYPE, $B (2020-2030)
  • TABLE 36 APAC GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2019)
  • TABLE 37 APAC GENERIC DRUGS MARKET, BY APPLICATION, $B (2020-2030)
  • TABLE 38 APAC GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2019)
  • TABLE 39 APAC GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020-2030)
  • TABLE 40 APAC GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2019)
  • TABLE 41 APAC GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020-2030)
  • TABLE 42 APAC GENERIC DRUGS MARKET, BY COUNTRY, $B (2014-2019)
  • TABLE 43 APAC GENERIC DRUGS MARKET, BY COUNTRY, $B (2020-2030)
  • TABLE 44 LATAM GENERIC DRUGS MARKET, BY TYPE, $B (2014-2019)
  • TABLE 45 LATAM GENERIC DRUGS MARKET, BY TYPE, $B (2020-2030)
  • TABLE 46 LATAM GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2019)
  • TABLE 47 LATAM GENERIC DRUGS MARKET, BY APPLICATION, $B (2020-2030)
  • TABLE 48 LATAM GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2019)
  • TABLE 49 LATAM GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020-2030)
  • TABLE 50 LATAM GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2019)
  • TABLE 51 LATAM GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020-2030)
  • TABLE 52 LATAM GENERIC DRUGS MARKET, BY COUNTRY, $B (2014-2019)
  • TABLE 53 LATAM GENERIC DRUGS MARKET, BY COUNTRY, $B (2020-2030)
  • TABLE 54 MEA GENERIC DRUGS MARKET, BY TYPE, $B (2014-2019)
  • TABLE 55 MEA GENERIC DRUGS MARKET, BY TYPE, $B (2020-2030)
  • TABLE 56 MEA GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2019)
  • TABLE 57 MEA GENERIC DRUGS MARKET, BY APPLICATION, $B (2020-2030)
  • TABLE 58 MEA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2019)
  • TABLE 59 MEA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020-2030)
  • TABLE 60 MEA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2019)
  • TABLE 61 MEA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020-2030)
  • TABLE 62 MEA GENERIC DRUGS MARKET, BY COUNTRY, $B (2014-2019)
  • TABLE 63 MEA GENERIC DRUGS MARKET, BY COUNTRY, $B (2020-2030)
  • TABLE 64 MAJOR PLAYERS AND THEIR OFFERINGS
  • TABLE 65 CIPLA LTD. - AT A GLANCE
  • TABLE 66 CIPLA LTD. - KEY FINANCIAL SUMMARY
  • TABLE 67 DR. REDDY'S LABORATORIES LTD. - AT A GLANCE
  • TABLE 68 DR. REDDY'S LABORATORIES LTD. - KEY FINANCIAL SUMMARY
  • TABLE 69 ALKEM LABORATORIES LIMITED - AT A GLANCE
  • TABLE 70 ALKEM LABORATORIES LIMITED - KEY FINANCIAL SUMMARY
  • TABLE 71 TEVA PHARMACEUTICAL INDUSTRIES LIMITED - AT A GLANCE
  • TABLE 72 TEVA PHARMACEUTICAL INDUSTRIES LIMITED - KEY FINANCIAL SUMMARY
  • TABLE 73 MYLAN N.V. - AT A GLANCE
  • TABLE 74 MYLAN N.V. - KEY FINANCIAL SUMMARY
  • TABLE 75 LUPIN LIMITED - AT A GLANCE
  • TABLE 76 LUPIN LIMITED - KEY FINANCIAL SUMMARY
  • TABLE 77 ENDO INTERNATIONAL PLC - AT A GLANCE
  • TABLE 78 ENDO INTERNATIONAL PLC - KEY FINANCIAL SUMMARY
  • TABLE 79 AUROBINDO PHARMA LIMITED - AT A GLANCE
  • TABLE 80 AUROBINDO PHARMA LIMITED - KEY FINANCIAL SUMMARY
  • TABLE 81 STADA ARZNEIMITTEL AG - AT A GLANCE
  • TABLE 82 STADA ARZNEIMITTEL AG - KEY FINANCIAL SUMMARY
  • TABLE 83 HIKMA PHARMACEUTICALS PLC - AT A GLANCE
  • TABLE 84 HIKMA PHARMACEUTICALS PLC - KEY FINANCIAL SUMMARY
  • TABLE 85 SAWAI PHARMACEUTICAL CO. LTD. - AT A GLANCE
  • TABLE 86 SAWAI PHARMACEUTICAL CO. LTD. - KEY FINANCIAL SUMMARY
  • TABLE 87 PIRAMAL ENTERPRISES LTD. - AT A GLANCE
  • TABLE 88 PIRAMAL ENTERPRISES LTD. - KEY FINANCIAL SUMMARY
  • TABLE 89 MALLINCKRODT PLC - AT A GLANCE
  • TABLE 90 MALLINCKRODT PLC - KEY FINANCIAL SUMMARY
  • TABLE 91 TORRENT PHARMACEUTICALS LTD. - AT A GLANCE
  • TABLE 92 TORRENT PHARMACEUTICALS LTD. - KEY FINANCIAL SUMMARY
  • TABLE 93 AMNEAL PHARMACEUTICALS INC. - AT A GLANCE
  • TABLE 94 AMNEAL PHARMACEUTICALS INC. - KEY FINANCIAL SUMMARY
  • TABLE 95 TARO PHARMACEUTICAL INDUSTRIES LTD. - AT A GLANCE
  • TABLE 96 TARO PHARMACEUTICAL INDUSTRIES LTD. - KEY FINANCIAL SUMMARY
  • TABLE 97 PERRIGO COMPANY PLC - AT A GLANCE
  • TABLE 98 PERRIGO COMPANY PLC - KEY FINANCIAL SUMMARY
  • TABLE 99 ALVOGEN - AT A GLANCE
  • TABLE 100 NICHI-IKO PHARMACEUTICAL CO. LTD. - AT A GLANCE
  • TABLE 101 NICHI-IKO PHARMACEUTICAL CO. LTD. - KEY FINANCIAL SUMMARY
  • TABLE 102 GLENMARK LIFE SCIENCES LIMITED - AT A GLANCE
  • TABLE 103 GLENMARK LIFE SCIENCES LIMITED - KEY FINANCIAL SUMMARY
  • TABLE 104 AMPHASTAR PHARMACEUTICALS INC. - AT A GLANCE
  • TABLE 105 AMPHASTAR PHARMACEUTICALS INC. - KEY FINANCIAL SUMMARY
  • TABLE 106 MSN LABS - AT A GLANCE
  • TABLE 107 CUSTOPHARM INC. - AT A GLANCE
  • TABLE 108 CADILA HEALTHCARE LTD. - AT A GLANCE
  • TABLE 109 CADILA HEALTHCARE LTD. - KEY FINANCIAL SUMMARY
  • TABLE 110 PFIZER INC. - AT A GLANCE
  • TABLE 111 PFIZER INC. - KEY FINANCIAL SUMMARY
  • TABLE 112 SANOFI - AT A GLANCE
  • TABLE 113 SANOFI - KEY FINANCIAL SUMMARY
  • TABLE 114 BAUSCH HEALTH COMPANIES INC. - AT A GLANCE
  • TABLE 115 BAUSCH HEALTH COMPANIES INC. - KEY FINANCIAL SUMMARY

LIST OF FIGURES

  • FIG 1 RESEARCH SCOPE
  • FIG 2 RESEARCH METHODOLOGY
  • FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY REGION
  • FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY INDUSTRY PARTICIPANT
  • FIG 5 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE
  • FIG 6 DATA TRIANGULATION APPROACH
  • FIG 7 CURRENCY CONVERSION RATES FOR USD (2019)
  • FIG 8 GLOBAL GENERIC DRUGS MARKET SUMMARY
  • FIG 9 BARGAINING POWER OF BUYERS
  • FIG 10 BARGAINING POWER OF SUPPLIERS
  • FIG 11 INTENSITY OF RIVALRY
  • FIG 12 THREAT OF NEW ENTRANTS
  • FIG 13 THREAT OF SUBSTITUTES
  • FIG 14 SNAPSHOT OF GLOBAL GENERIC DRUGS MARKET
  • FIG 15 GLOBAL GENERIC DRUGS MARKET, BY TYPE, $B (2014-2030)
  • FIG 16 GLOBAL GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2030)
  • FIG 17 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2030)
  • FIG 18 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2030)
  • FIG 19 WORLDWIDE MAJOR MARKETS FOR GENERIC DRUGS
  • FIG 20 GLOBAL GENERIC DRUGS MARKET, BY REGION, $B (2014-2030)
  • FIG 21 NORTH AMERICA GENERIC DRUGS MARKET SNAPSHOT
  • FIG 22 NORTH AMERICA GENERIC DRUGS MARKET, BY TYPE, $B (2014-2030)
  • FIG 23 NORTH AMERICA GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2030)
  • FIG 24 NORTH AMERICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2030)
  • FIG 25 NORTH AMERICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2030)
  • FIG 26 NORTH AMERICA GENERIC DRUGS MARKET, BY COUNTRY, $B (2014-2030)
  • FIG 27 EUROPE GENERIC DRUGS MARKET SNAPSHOT
  • FIG 28 EUROPE GENERIC DRUGS MARKET, BY TYPE, $B (2014-2030)
  • FIG 29 EUROPE GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2030)
  • FIG 30 EUROPE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2030)
  • FIG 31 EUROPE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2030)
  • FIG 32 EUROPE GENERIC DRUGS MARKET, BY COUNTRY, $B (2014-2030)
  • FIG 33 APAC GENERIC DRUGS MARKET SNAPSHOT
  • FIG 34 APAC GENERIC DRUGS MARKET, BY TYPE, $B (2014-2030)
  • FIG 35 APAC GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2030)
  • FIG 36 APAC GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2030)
  • FIG 37 APAC GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2030)
  • FIG 38 APAC GENERIC DRUGS MARKET, BY COUNTRY, $B (2014-2030)
  • FIG 39 LATAM GENERIC DRUGS MARKET SNAPSHOT
  • FIG 40 LATAM GENERIC DRUGS MARKET, BY TYPE, $B (2014-2030)
  • FIG 41 LATAM GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2030)
  • FIG 42 LATAM GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2030)
  • FIG 43 LATAM GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2030)
  • FIG 44 LATAM GENERIC DRUGS MARKET, BY COUNTRY, $B (2014-2030)
  • FIG 45 MEA GENERIC DRUGS MARKET SNAPSHOT
  • FIG 46 MEA GENERIC DRUGS MARKET, BY TYPE, $B (2014-2030)
  • FIG 47 MEA GENERIC DRUGS MARKET, BY APPLICATION, $B (2014-2030)
  • FIG 48 MEA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014-2030)
  • FIG 49 MEA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014-2030)
  • FIG 50 MEA GENERIC DRUGS MARKET, BY COUNTRY, $B (2014-2030)
  • FIG 51 CIPLA LTD. - REVENUE SPLIT BY THERAPY AND GEOGRAPHY (2019)
  • FIG 52 DR. REDDY'S LABORATORIES LTD. - REVENUE SPLIT BY BUSSINESS SEGMENT AND GEOGRAPHY (2019)
  • FIG 53 ALKEM LABORATORIES LIMITED - REVENUE SPLIT BY GEOGRAPHY (2019)
  • FIG 54 TEVA PHARMACEUTICAL INDUSTRIES LIMITED - REVENUE SPLIT BY GEOGRAPHY (2019)
  • FIG 55 MYLAN N.V. - REVENUE SPLIT BY THERAPEUTIC AREA AND GEOGRAPHY (2019)
  • FIG 56 LUPIN LIMITED - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)
  • FIG 57 ENDO INTERNATIONAL PLC - REVENUE SPLIT BY DIVISION (2019)
  • FIG 58 AUROBINDO PHARMA LIMITED - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 59 STADA ARZNEIMITTEL AG - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 60 HIKMA PHARMACEUTICALS PLC - REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2019)
  • FIG 61 SAWAI PHARMACEUTICAL CO. LTD. - REVENUE SPLIT BY GEOGRAPHY (2019)
  • FIG 62 PIRAMAL ENTERPRISES LTD. - REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2019)
  • FIG 63 MALLINCKRODT PLC - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 64 TORRENT PHARMACEUTICALS LTD. - REVENUE SPLIT BY GEOGRAPHY (2019)
  • FIG 65 AMNEAL PHARMACEUTICALS INC. - REVENUE SPLIT BY SEGMENT (2019)
  • FIG 66 TARO PHARMACEUTICAL INDUSTRIES LTD. - REVENUE SPLIT BY GEOGRAPHY (2020)
  • FIG 67 PERRIGO COMPANY PLC - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 68 NICHI-IKO PHARMACEUTICAL CO. LTD. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 69 GLENMARK LIFE SCIENCES LIMITED - REVENUE SPLIT BY GEOGRAPHY (2019)
  • FIG 70 AMPHASTAR PHARMACEUTICALS INC. - REVENUE SPLIT BY GEOGRAPHY (2019)
  • FIG 71 CADILA HEALTHCARE LTD. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 72 PFIZER INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 73 SANOFI - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 74 BAUSCH HEALTH COMPANIES INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
目次
Product Code: LS12164

Almost 75% of the deaths in 2020 were because of chronic diseases, as per the World Health Organization (WHO). Among the diseases, the deadliest were ischemic heart disease, diabetes, cancer, and stroke. This is to be a major factor to propel the global generic drugs market size to $786.0 billion by 2030 from $278.4 billion in 2019, at a 10.0% CAGR between 2020 and 2030. This is because branded drugs are often expensive, which is why a large number of people in developing countries are not able to purchase them.

Generic drugs, on the other hand, are cost-effective, at the same time contain the same active ingredients and have a similar effect as patented drugs. In this regard, the generic drugs market is also being driven by the patent expiry of blockbuster medications. As patented drugs lose their certification, it gives pharmaceutical companies the opportunity to create their cheaper but equally effective variants.

During the COVID-19 crisis, the generic drugs market has received a boost, as governments around the world, despite implementing lockdowns and movement restrictions, have ensured that the supply of essential medicines isn't hampered. Moreover, as people have lost their jobs or are working at reduced salaries, they are drastically cutting down on expenses, which is why the preference for cheap generic drugs over the expensive patented ones has risen.

In the near future, the highest CAGR in the generic drugs market, of 10.4%, is predicted to be displayed by the oral category, on the basis of route of administration. Being the simplest and a painless method of drug administration, it is widely popular among the masses.

The indirect bifurcation generates the higher revenue in the generic drugs market, under the distribution channel segment. Most people prefer to buy drugs from hospitals, clinics, and pharmacies/chemists, which are all increasing in number around the world due to the mounting patient count.

Asia-Pacific (APAC) has made the largest revenue contribution to the generic drugs market till now, and it will continue doing so throughout this decade. The growing geriatric population and burden of acute and chronic diseases are driving the demand for medication. Moreover, the majority of the people here still cannot afford expensive medicines, which is why they go for the cost-effective generic drugs.

Major global generic drugs market players include Dr. Reddy's Laboratories Ltd., Cipla Ltd., Alkem Laboratories Limited, Mylan N.V., Teva Pharmaceutical Industries Limited, Lupin Limited, Aurobindo Pharma Limited, Endo International plc, STADA Arzneimittel AG, Sawai Pharmaceutical Co. Ltd., Hikma Pharmaceuticals plc, Piramal Enterprises Ltd., Torrent Pharmaceuticals Ltd., Mallinckrodt plc, Amneal Pharmaceuticals Inc., Perrigo Company plc, Taro Pharmaceutical Industries Ltd., Alvogen, Glenmark Life Sciences Limited, Nichi-Iko Pharmaceutical Co. Ltd., Amphastar Pharmaceuticals Inc., CUSTOPHARM INC., MSN Labs, Cadila Healthcare Ltd., Sanofi, Pfizer Inc., and Bausch Health Companies Inc.

Table of Contents

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Market Definition
  • 1.3 Research Scope
    • 1.3.1 Market Segmentation by Type
    • 1.3.2 Market Segmentation by Application
    • 1.3.3 Market Segmentation by Route of Administration
    • 1.3.4 Market Segmentation by Distribution Channel
    • 1.3.5 Market Segmentation by Region
    • 1.3.6 Analysis Period
    • 1.3.7 Market Data Reporting Unit
  • 1.4 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
  • 2.2 Primary Research
    • 2.2.1 Breakdown of Primary Research Respondents
      • 2.2.1.1 By region
      • 2.2.1.2 By industry participant
      • 2.2.1.3 By company type
  • 2.3 Market Size Estimation
  • 2.4 Data Triangulation
  • 2.5 Currency Conversion Rates
  • 2.6 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

  • 4.1 Market Definition
    • 4.1.1 By Type
      • 4.1.1.1 Simple
      • 4.1.1.2 Super
      • 4.1.1.3 Biosimilars
    • 4.1.2 By Application
      • 4.1.2.1 Neurological diseases
      • 4.1.2.2 Cardiological diseases
      • 4.1.2.3 Metabolic diseases
      • 4.1.2.4 Infectious diseases
      • 4.1.2.5 Orthopedic diseases
      • 4.1.2.6 Respiratory diseases
      • 4.1.2.7 Genitourinary/hormonal diseases
      • 4.1.2.8 Others
    • 4.1.3 By Route of Administration
      • 4.1.3.1 Oral
      • 4.1.3.2 Injection
      • 4.1.3.3 Cutaneous
      • 4.1.3.4 Mucosal
      • 4.1.3.5 Inhalation
      • 4.1.3.6 Others
    • 4.1.4 By Distribution Channel
      • 4.1.4.1 Indirect
      • 4.1.4.2 Direct
  • 4.2 Market Dynamics
    • 4.2.1 Trends
      • 4.2.1.1 Shift in preference toward generic drugs
      • 4.2.1.2 Increasing product launches
      • 4.2.1.3 Rising number of collaborations and partnerships
      • 4.2.1.4 Increasing number of mergers and acquisitions
    • 4.2.2 Drivers
      • 4.2.2.1 Increasing ageing population
      • 4.2.2.2 Patent expiration of blockbuster drugs
      • 4.2.2.3 Growing prevalence of acute and chronic diseases
      • 4.2.2.4 Rising R&D expenditure of biotech and pharma companies
      • 4.2.2.5 Impact analysis of drivers on market forecast
    • 4.2.3 Restraints
      • 4.2.3.1 High marketing of branded drugs overshadows generics
      • 4.2.3.2 Preference of physicians toward branded drugs
      • 4.2.3.3 Impact analysis of restraints on market forecast
    • 4.2.4 Opportunities
      • 4.2.4.1 Supportive regulations for generics
  • 4.3 Impact of COVID-19
    • 4.3.1 Supply Side Analysis
      • 4.3.1.1 Current scenario of major manufactures and exporters of generic products
      • 4.3.1.2 Situation of lockdown and workforce availability
      • 4.3.1.3 Production scenario
      • 4.3.1.4 Situation of major countries supplying generic drugs
    • 4.3.2 Demand Side Analysis
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Buyers
    • 4.4.2 Bargaining Power of Suppliers
    • 4.4.3 Intensity of Rivalry
    • 4.4.4 Threat of New Entrants
    • 4.4.5 Threat of Substitutes

Chapter 5. Global Market Size and Forecast

  • 5.1 By Type
  • 5.2 By Application
  • 5.3 By Route of Administration
  • 5.4 By Distribution Channel
  • 5.5 By Region

Chapter 6. North America Market Size and Forecast

  • 6.1 By Type
  • 6.2 By Application
  • 6.3 By Route of Administration
  • 6.4 By Distribution Channel
  • 6.5 By Country

Chapter 7. Europe Market Size and Forecast

  • 7.1 By Type
  • 7.2 By Application
  • 7.3 By Route of Administration
  • 7.4 By Distribution Channel
  • 7.5 By Country

Chapter 8. APAC Market Size and Forecast

  • 8.1 By Type
  • 8.2 By Application
  • 8.3 By Route of Administration
  • 8.4 By Distribution Channel
  • 8.5 By Country

Chapter 9. LATAM Market Size and Forecast

  • 9.1 By Type
  • 9.2 By Application
  • 9.3 By Route of Administration
  • 9.4 By Distribution Channel
  • 9.5 By Country

Chapter 10. MEA Market Size and Forecast

  • 10.1 By Type
  • 10.2 By Application
  • 10.3 By Route of Administration
  • 10.4 By Distribution Channel
  • 10.5 By Country

Chapter 11. Competitive Landscape

  • 11.1 Strategic Developments of Key Players
    • 11.1.1 Product Launches and Approvals
    • 11.1.2 Partnerships
  • 11.2 Major Players and Their Offerings

Chapter 12. Company Profiles

  • 12.1 Cipla Ltd.
    • 12.1.1 Business Overview
    • 12.1.2 Product and Service Offerings
    • 12.1.3 Key Financial Summary
  • 12.2 Dr. Reddy's Laboratories Ltd.
    • 12.2.1 Business Overview
    • 12.2.2 Product and Service Offerings
    • 12.2.3 Key Financial Summary
  • 12.3 Alkem Laboratories Limited
    • 12.3.1 Business Overview
    • 12.3.2 Product and Service Offerings
    • 12.3.3 Key Financial Summary
  • 12.4 Teva Pharmaceutical Industries Limited
    • 12.4.1 Business Overview
    • 12.4.2 Product and Service Offerings
    • 12.4.3 Key Financial Summary
  • 12.5 Mylan N.V.
    • 12.5.1 Business Overview
    • 12.5.2 Product and Service Offerings
    • 12.5.3 Key Financial Summary
  • 12.6 Lupin Limited
    • 12.6.1 Business Overview
    • 12.6.2 Product and Service Offerings
    • 12.6.3 Key Financial Summary
  • 12.7 Endo International plc
    • 12.7.1 Business Overview
    • 12.7.2 Product and Service Offerings
    • 12.7.3 Key Financial Summary
  • 12.8 Aurobindo Pharma Limited
    • 12.8.1 Business Overview
    • 12.8.2 Product and Service Offerings
    • 12.8.3 Key Financial Summary
  • 12.9 STADA Arzneimittel AG
    • 12.9.1 Business Overview
    • 12.9.2 Product and Service Offerings
    • 12.9.3 Key Financial Summary
  • 12.10 Hikma Pharmaceuticals plc
    • 12.10.1 Business Overview
    • 12.10.2 Product and Service Offerings
    • 12.10.3 Key Financial Summary
  • 12.11 Sawai Pharmaceutical Co. Ltd.
    • 12.11.1 Business Overview
    • 12.11.2 Product and Service Offerings
    • 12.11.3 Key Financial Summary
  • 12.12 Piramal Enterprises Ltd.
    • 12.12.1 Business Overview
    • 12.12.2 Product and Service Offerings
    • 12.12.3 Key Financial Summary
  • 12.13 Mallinckrodt plc
    • 12.13.1 Business Overview
    • 12.13.2 Product and Service Offerings
    • 12.13.3 Key Financial Summary
  • 12.14 Torrent Pharmaceuticals Ltd.
    • 12.14.1 Business Overview
    • 12.14.2 Product and Service Offerings
    • 12.14.3 Key Financial Summary
  • 12.15 Amneal Pharmaceuticals Inc.
    • 12.15.1 Business Overview
    • 12.15.2 Product and Service Offerings
    • 12.15.3 Key Financial Summary
  • 12.16 Taro Pharmaceutical Industries Ltd.
    • 12.16.1 Business Overview
    • 12.16.2 Product and Service Offerings
    • 12.16.3 Key Financial Summary
  • 12.17 Perrigo Company plc
    • 12.17.1 Business Overview
    • 12.17.2 Product and Service Offerings
    • 12.17.3 Key Financial Summary
  • 12.18 Alvogen
    • 12.18.1 Business Overview
    • 12.18.2 Product and Service Offerings
  • 12.19 Nichi-Iko Pharmaceutical Co. Ltd.
    • 12.19.1 Business Overview
    • 12.19.2 Product and Service Offerings
    • 12.19.3 Key Financial Summary
  • 12.20 Glenmark Life Sciences Limited
    • 12.20.1 Business Overview
    • 12.20.2 Product and Service Offerings
    • 12.20.3 Key Financial Summary
  • 12.21 Amphastar Pharmaceuticals Inc.
    • 12.21.1 Business Overview
    • 12.21.2 Product and Service Offerings
    • 12.21.3 Key Financial Summary
  • 12.22 MSN Labs
    • 12.22.1 Business Overview
    • 12.22.2 Product and Service Offerings
  • 12.23 CUSTOPHARM INC.
    • 12.23.1 Business Overview
    • 12.23.2 Product and Service Offerings
  • 12.24 Cadila Healthcare Ltd.
    • 12.24.1 Business overview
    • 12.24.2 Product and Service Offerings
    • 12.24.3 Key Financial Summary
  • 12.25 Pfizer Inc.
    • 12.25.1 Business Overview
    • 12.25.2 Product and Service Offerings
    • 12.25.3 Key Financial Summary
  • 12.26 Sanofi
    • 12.26.1 Business Overview
    • 12.26.2 Product and Service Offerings
    • 12.26.3 Key Financial Summary
  • 12.27 Bausch Health Companies Inc.
    • 12.27.1 Business Overview
    • 12.27.2 Product and Service Offerings
    • 12.27.3 Key Financial Summary

Chapter 13. Appendix

  • 13.1 Abbreviations
  • 13.2 Sources and References
  • 13.3 Related Reports